At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week,Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating LY2428757 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 247 participants across 60 sites in 11 countries.
Detailed Summary
A multicenter, multinational, randomized,double-blind, placebo-controlled study in patients with Type 2 Diabetes Mellitus (T2DM). Patients with inadequate glycemic control using diet and exercise alone, or in combination with metformin, will be enrolled. The primary objective of this study is to test the hypothesis that LY2428757 given to patients with T2DM inadequately controlled with diet and exercise alone, or metformin monotherapy, produces a significant decrease in the mean hemoglobin A1c (HbA1c) from baseline to endpoint at 12 weeks as compared to placebo. Trial consists of 12 weeks of double-blind treatment and 4-week safety follow-up.
Study Details
Timeline
Interventions
Once weekly for 12 weeks as a subcutaneous injection.
1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.